News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atossa Genetics, Inc. (ATOS) to Sponsor Power of Pink Event in Johns Creek, Georgia



9/20/2013 10:58:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATLANTA, GA--(Marketwired - September 20, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS) is proud to announce its sponsorship of The Third Annual Power of Pink luncheon, fashion show and silent auction. The event will take place at the Country Club of the South in Johns Creek, Georgia, on Friday, September 20, 2013.

This year, North Fulton Hospital, through its Check-Up for Chicks program, is again taking a stand in the fight against breast cancer with the Power of Pink. More than 300 of North Atlanta's most passionate supporters of breast health and breast cancer research will be in attendance.

"We are proud to sponsor this important annual event in the quest to raise breast cancer awareness and fight this devastating disease," stated Chris Destro, VP of Sales & Marketing at Atossa. In addition to sponsoring events and supporting efforts like Power of Pink, we are contributing to the fight against breast cancer with the national rollout of our ForeCYTE Breast Health Test. The ForeCYTE test is a revolutionary new product that detects reversible precancerous conditions in the breast approximately 8 years before they become cancer, enabling physicians and their patients to obtain valuable, science-based information to manage their breast health."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. The test can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit www.atossagenetics.com and www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit www.getforecyte.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


Contact:

Atossa Genetics, Inc.
Chris Destro
Vice President
(O) 800-351-3902
(M) 206-310-2335
Email Contact

MBS Value Partners, LLC (Investors)
Matthew D. Haines
Managing Director
(O) 212-710-9686
Email Contact

JQA Partners, LLC (media)
Jules Abraham
Principal
(O) 917-885-7378
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES